Infographic: Testing for EGFR mutations in non-small cell lung cancer

Roche leads the way in detecting EGFR mutations associated with lung cancer


Approximately 10-40%1 of patients with non-small cell lung cancer show tumour associated mutations in the Epidermal Growth Factor Receptor (EGFR) found on the surface of every cell. Identifying these mutations can help determine what medication a person can receive.

Biopsies have traditionally proven useful in this identification and in predicting response and treatment resistance. The health condition of the patient or the location of the tumour, however, often make it difficult to resect enough tissue for biomarker testing.


Liquid biopsy testing

Liquid biopsy testing is a simple and non - invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample. This additionally allows for repeat testing to better monitor patient response. (cobas® EGFR Mutation Test (with or without v2) is not approved with a monitoring claim in the U.S.)


Infographic: Testing for EGFR Mutations


  1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129 - 39.